The additive clinical value of combined thyroglobulin and antithyroglobulin antibody measurements to define persistent and recurrent disease in patients with differentiated thyroid cancer

Nuclear Medicine Communications

Volumn 29, Issue 10, 2008, Pages 880-884

  Aras, Gülseren ^a   Gültekin, Salih Sinan ^a   Küçük, Nuriye Özlem ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

Antithyroglobulin antibody; Differentiated thyroid carcinoma; Progressive disease; Thyroglobulin

Indexed keywords

BIOLOGICAL MARKER; IODINE 131; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PERTECHNETIC ACID TC 99M; THYROGLOBULIN; THYROGLOBULIN ANTIBODY; THYROTROPIN; ANTI THYROGLOBULIN; ANTI-THYROGLOBULIN; AUTOANTIBODY; TUMOR MARKER; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; CANCER DIAGNOSIS; CHILD; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; ECHOGRAPHY; FEMALE; FOLLOW UP; FREE LIOTHYRONINE INDEX; FREE THYROXINE INDEX; HUMAN; HYPOTHYROIDISM; IMMUNORADIOMETRIC ASSAY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MAXIMUM ALLOWABLE CONCENTRATION; METASTASIS; RADIOISOTOPE THERAPY; RECURRENT CANCER; ROC CURVE; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; THYROGLOBULIN BLOOD LEVEL; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROID SCINTISCANNING; THYROTROPIN BLOOD LEVEL; WHOLE BODY SCINTISCANNING; BLOOD; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; THYROID TUMOR; TUMOR RECURRENCE;

ADOLESCENT; ADULT; AGED; AUTOANTIBODIES; CHILD; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; THYROGLOBULIN; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 58749092848     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e328308e079     Document Type: Article

References (19)

1. Grebe SKG, Hay ID. Follicular cell-derived thyroid carcinoma. Cancer Treat Res 1997; 89:91-140.
2. Pacini F, Capezzone M, Elisei R, Ceccarelli C, Taddei D, Pinchera A. Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab 2002; 87:1499-1501.
3. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003; 88:1433-1441.
4. Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999; 84:3877-3885.
5. Lissitzky S. Thyroglobulin entering into molecular biology. J Endocrinol Invest 1984; 7:65-76.
6. Spencer CA, Takeuchi M, Kazarosyan M, Wang CC, Guttler RB, Singer PA, et al. Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 1998; 83:1121-1127.
7. Rubello D, Girelli ME, Casara D, Piccolo M, Perin A, Busnardo B. Usefulness of the combined antithyroglobulin antibodies and thyroglobulin assay in the follow-up of patients with differentiated thyroid cancer. J Endocrinol Invest 1990; 13:737-742.
8. Kumar A, Shah DH, Shrihari U, Dandekar SR, Vijayan U, Sharma SM. Significance of antithyroglobulin autoantibodies in differentiated thyroid carcinoma. Thyroid 1994; 4:199-202.
9. Feldt-Rasmussen U, Schlumberger M. European interlaboratory comparison of serum thyroglobulin measurement. J Endocrinol Invest 1988; 11:175-181.
10. Spencer CA, Takeuchi M, Kazarosyan M. Current status and performance goals for serum thyroglobulin assays. Clin Chem 1996; 42:164-173.
11. 99mTc-MIBI scans. Nucl Med Commun 2006; 27:873-876.
12. Schlumberger M, Baudin E. Serum thyroglobulin determination in the follow-up of patients with differentiated thyroid carcinoma. Eur J Endocrinol 1998; 138:249-252.
13. Pacini F, Mariotti S. Thyroid autoantibodies in thyroid cancer: incidence and relationship with tumour outcome. Acta Endocrinol 1988; 119:373-380.
14. Rubello D, Casara D. Clinical meaning of circulating ATG in differentiated thyroid cancer: a prospective study. J Nucl Med 1992; 33:1478-1480.
15. Ericsson UB, Christensen SB, Thorel JI. A high prevalence of thyroglobulin autoantibodies in adults with and without thyroid disease as measured with a sensitive solid-phase immunosorbent radioassay. Clin Immunol Immunopathol 1985; 37:154-162.
16. Belfiore A, Russo D, Vigneri R, Filetti S. Graves' disease, thyroid nodules and thyroid cancer. Clin Endocrinol 2001; 35:711-718.
17. Matsubayashi S, Kawai K, Matsumoto Y, Mukuta T, Morita T, Hirai K, et al. The correlation between papillary thyroid carcinoma and lymphocytic infiltration in the thyroid gland. J Clin Endocrinol Metab 1995; 80:3421-3424.
18. Pellegriti G, Belfiore A, Giuffrida D, Lupo R, Vigneri R. Outcome of the differentiated thyroid cancer in Graves' patients. J Clin Endocrinol Metab 1998; 83:2805-2809.
19. Pacini F. Follow-up of differentiated thyroid cancer. Eur J Nucl Med 2002; 29:492-496.